Abstract
SummaryTumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor glioblastoma. We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74–0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95–0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70–1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients.
Highlights
Several blood-based biosources, such as plasma, serum, plasma-derived extracellular vesicles, and circulating tumor cells, are currently being evaluated as liquid biopsies for many types of cancer.[1,2] brain tumors are notoriously difficult to detect in blood.[3,4,5,6] Analysis of cerebrospinal fluid collected from patients with diffuse glioma revealed the presence of multiple molecular biomarkers.[7]
We have shown that tumor-educated platelets (TEPs) are a potential biosource for blood-based cancer diagnostics[18,19,20] by using the highly multiplexed biomarker detection platform thromboSeq.[21]
We show that Tumor-educated platelets (TEPs) RNA profiles of patients with glioblastoma are different from those of asymptomatic healthy controls
Summary
Several blood-based biosources, such as plasma, serum, plasma-derived extracellular vesicles, and circulating tumor cells, are currently being evaluated as liquid biopsies for many types of cancer.[1,2] brain tumors are notoriously difficult to detect in blood.[3,4,5,6] Analysis of cerebrospinal fluid collected from patients with diffuse glioma revealed the presence of multiple molecular biomarkers.[7]. 20%–73% of patients with glioblastoma, depending on the detection method applied.[10,11,12] Detection of brain cancer in blood might leverage the use of such ‘‘liquid biopsies’’ for analysis of tumor progression, tumor recurrence, therapy response prediction, and monitoring[13] and for differentiating glioblastoma tumor progression from false positive progression (pseudo-progression or radiation necrosis) after initial therapy.[3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
